Shermock KM - Search Results

1

Evaluating the Impact of Prescription Fill Rates on Risk Stratification Model Performance.

Chang HY, Richards TM, Shermock KM, Elder Dalpoas S, J Kan H, Alexander GC, Weiner JP, Kharrazi H. Chang HY, et al. Among authors: shermock km. Med Care. 2017 Dec;55(12):1052-1060. doi: 10.1097/MLR.0000000000000825. Med Care. 2017. PMID: 29036011

2

Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.

Chang HY, Kan HJ, Shermock KM, Alexander GC, Weiner JP, Kharrazi H. Chang HY, et al. Among authors: shermock km. J Manag Care Spec Pharm. 2020 Oct;26(10):1282-1290. doi: 10.18553/jmcp.2020.26.10.1282. J Manag Care Spec Pharm. 2020. PMID: 32996394 Free PMC article.

3

Development of measurable criteria to identify and prioritize patients for inclusion in comprehensive medication management programs within primary care settings.

Bishop MA, Chang HY, Kitchen C, Weiner JP, Kharrazi H, Shermock KM. Bishop MA, et al. Among authors: shermock km. J Manag Care Spec Pharm. 2021 Aug;27(8):1009-1018. doi: 10.18553/jmcp.2021.27.8.1009. J Manag Care Spec Pharm. 2021. PMID: 34337988 Free PMC article.

4

Comparing and validating medication complexity from insurance claims against electronic health records.

Kitchen CA, Chang HY, Bishop MA, Shermock KM, Kharrazi H, Weiner JP. Kitchen CA, et al. Among authors: shermock km. J Manag Care Spec Pharm. 2022 Apr;28(4):473-484. doi: 10.18553/jmcp.2022.28.4.473. J Manag Care Spec Pharm. 2022. PMID: 35332787 Free PMC article.

5

Claims-based pharmacy markers for comprehensive medication management program case identification: Validation against concurrent and prospective healthcare costs and utilization.

Chang HY, Kitchen C, Bishop MA, Shermock KM, Gudzune KA, Kharrazi H, Weiner JP. Chang HY, et al. Among authors: shermock km. Res Social Adm Pharm. 2022 Oct;18(10):3800-3813. doi: 10.1016/j.sapharm.2022.04.006. Epub 2022 May 6. Res Social Adm Pharm. 2022. PMID: 35550347

6

Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.

Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM. Moore TJ, et al. Among authors: shermock km. JAMA Intern Med. 2021 Jan 1;181(1):52-60. doi: 10.1001/jamainternmed.2020.3997. JAMA Intern Med. 2021. PMID: 33031559 Free PMC article.

7

Evaluation of Bedside Delivery of Medications Before Discharge: Effect on 30-Day Readmission.

Segal JB, Apfel A, Brotman DJ, Shermock KM, Clark JM. Segal JB, et al. Among authors: shermock km. J Manag Care Spec Pharm. 2020 Mar;26(3):296-304. doi: 10.18553/jmcp.2020.26.3.296. J Manag Care Spec Pharm. 2020. PMID: 32105180 Free PMC article.

8

Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.

Seal BS, Anderson S, Shermock KM. Seal BS, et al. Among authors: shermock km. J Manag Care Spec Pharm. 2016 Mar;22(3):227-35. doi: 10.18553/jmcp.2016.22.3.227. J Manag Care Spec Pharm. 2016. PMID: 27003552 Free PMC article.

9

Questionable impact of Universal Medication Schedule.

Shermock KM. Shermock KM. Am J Health Syst Pharm. 2020 Sep 18;77(19):1545-1546. doi: 10.1093/ajhp/zxaa235. Am J Health Syst Pharm. 2020. PMID: 32729613 No abstract available.

10

Impact of Displaying Inpatient Pharmaceutical Costs at the Time of Order Entry: Lessons From a Tertiary Care Center.

Conway S, Brotman D, Pinto B, Merola D, Feldman L, Miller R, Shermock K. Conway S, et al. J Hosp Med. 2017 Aug;12(8):639-645. doi: 10.12788/jhm.2779. J Hosp Med. 2017. PMID: 28786430

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters